Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 12/20 | 0.88 |
| ▸ | PDE4A | P27815 | 9/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746332 | 0.96 | TNF (0.81) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6099935 | 0.92 | PDE4A (0.74) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7746632 | 0.85 | PDE4A (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7748803 | 0.85 | TNF (0.86) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23000623 | 0.85 | PDE4A (0.80) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6095763 | 0.85 | TNF (0.63) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7847569 | 0.85 | TNF (0.63) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1194579 | 0.84 | PDE4B (0.74) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7741608 | 0.83 | TNF (0.88) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30568371 | 0.83 | TNF (0.88) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3782983-A1 | ISOINDOLE DERIVATIVE | Tianjin Hemay Pharmaceutical Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201255-A1 | ISOINDOLE DERIVATIVE | 天津合美医药科技有限公司 | 2019-10-24 | — | — | WO | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | COX4I1, ALDH1A2, GDI2 | TNF 4588/4885PDE4A 1740/4885PDE4B 1378/4885 |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | COX4I1, ALDH1A2, GDI2 | TNF 4588/4885PDE4A 1740/4885PDE4B 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.